NYSE:ABTMedical Equipment
Why Abbott (ABT) Is Up 7.4% After Mixed Q2 Results And Expanded Heart Device, Diagnostics Push
Abbott Laboratories recently reported second-quarter 2026 results showing sales rising to US$12,593 million from US$11,142 million a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations slipped to US$0.53 from US$1.01.
At the same time, Abbott is strengthening its medical device and diagnostics portfolio with a large real-world TriClip heart valve study and ongoing expansion in diabetes and oncology testing, which could reshape how investors view...